Published online Jan 12, 2023. doi: 10.13105/wjma.v11.i1.29
Peer-review started: August 25, 2022
First decision: October 4, 2022
Revised: October 13, 2022
Accepted: November 23, 2022
Article in press: November 23, 2022
Published online: January 12, 2023
Processing time: 245 Days and 16.4 Hours
Post-coronavirus disease 2019 (COVID-19) cholangiopathy is a recently identified clinical entity that develops during the recovery phase from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Early recognition of this complication is critical to ensure prompt and adequate management, which could affect the prognosis of these patients.
The main objectives of this review were to identify the available data contained in the studies accessible from the literature concerning post-COVID-19 cholangiopathy.
We have searched within two electronic databases (PubMed and the Cochrane Library) works on this topic, published between January 1, 2020 to August 22, 2022, using MeSH terms and free-language keywords: cholangiopathy; COVID-19; post-COVID-19 cholangiopathy; SARS-CoV-2.
Thirteen studies were included in this descriptive review, which included 64 patients suffering from this condition.
This review analyzed the possible causes and the clinical course of post-COVID-19 cholangiopathy, aiming to understand both its possible causes and its consequent clinical evolution.
Cholangiopathy is a medium-to-long-term complication of this virus, in which biliary damage is generally progressive up to liver failure. Researchers should focus on both early recognition and timely treatment of this complication.